{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:01:23Z","timestamp":1773889283296,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002635","name":"Inha University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002635","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korean Health Technology R&D","award":["NRF-2012-0002988"],"award-info":[{"award-number":["NRF-2012-0002988"]}]},{"name":"Korean Health Technology R&D","award":["2012R1A2A2A01045602"],"award-info":[{"award-number":["2012R1A2A2A01045602"]}]},{"name":"Ministry of Health and Welfare"},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea (NRF)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.canlet.2014.03.012","type":"journal-article","created":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T14:24:04Z","timestamp":1395411844000},"page":"50-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["HS-438, a new inhibitor of Imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia"],"prefix":"10.1016","volume":"348","author":[{"given":"Sun-Mi","family":"Yun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Hee","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenghuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Kwon","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunseung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JinHee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghye","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungwoo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon-Sun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2014.03.012_b0005","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2014.03.012_b0010","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.canlet.2014.03.012_b0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2014.03.012_b0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.canlet.2014.03.012_b0025","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2004-04-1242","article-title":"The Jab1\/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression","volume":"105","author":"Tomoda","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.03.012_b0030","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2002-06-1756","article-title":"Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia","volume":"102","author":"Hofmann","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.03.012_b0035","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"5","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2014.03.012_b0040","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1517\/13543784.17.6.865","article-title":"New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check","volume":"17","author":"O\u2019Hare","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.canlet.2014.03.012_b0045","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canlet.2014.03.012_b0050","first-page":"207","article-title":"Nilotinib for the treatment of chronic myeloid leukemia: an evidence-based review","volume":"4","author":"Jabbour","year":"2010","journal-title":"Core Evid"},{"key":"10.1016\/j.canlet.2014.03.012_b0055","first-page":"121","article-title":"Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance","volume":"1","author":"Martinelli","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.canlet.2014.03.012_b0060","first-page":"7149","article-title":"Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)","volume":"62","author":"La Ros\u00e9e","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.03.012_b0065","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1021\/jm301891t","article-title":"Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant","volume":"56","author":"Hong","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.canlet.2014.03.012_b0070","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0962-8924(01)02173-0","article-title":"Programmed cell death: alive and well in the new millennium","volume":"11","author":"Kaufmann","year":"2001","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.canlet.2014.03.012_b0075","first-page":"485","article-title":"Role of the BCR-ABL oncogene in human leukemia: fifteenth Richard and Hinda Rosenthal Foundation Award Lecture","volume":"53","author":"Witte","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.03.012_b0080","first-page":"F217","article-title":"Protein tyrosine kinases and cancer","volume":"1333","author":"Kolibaba","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.canlet.2014.03.012_b0085","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2014.03.012_b0090","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1373\/clinchem.2004.031112","article-title":"Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib","volume":"50","author":"Soverini","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.canlet.2014.03.012_b0095","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canlet.2014.03.012_b0100","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: the new wave of BCR-ABL inhibitors","volume":"6","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.canlet.2014.03.012_b0105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.canlet.2006.12.004","article-title":"Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680","volume":"251","author":"Cheetham","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2014.03.012_b0110","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1073\/pnas.0408283102","article-title":"A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance","volume":"102","author":"Gumireddy","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canlet.2014.03.012_b0115","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/leu.2008.74","article-title":"Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism","volume":"22","author":"Zhang","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2014.03.012_b0120","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood-2005-07-2966","article-title":"Adaphostin-induced oxidative stress overcomes BCR\/ABL mutation-dependent and -independent imatinib resistance","volume":"107","author":"Chandra","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.03.012_b0125","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nsb770","article-title":"Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site","volume":"9","author":"Pargellis","year":"2002","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.canlet.2014.03.012_b0130","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/0008-5472.CAN-05-2788","article-title":"Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680","volume":"66","author":"Young","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.03.012_b0135","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.03.012_b0140","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0300-483X(02)00460-2","article-title":"Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis","volume":"181\u2013182","author":"Pietenpol","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/j.canlet.2014.03.012_b0145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2007.10.012","article-title":"CDK inhibitors in cancer therapy: what is next?","volume":"29","author":"Malumbres","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.canlet.2014.03.012_b0150","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1042\/BST20120092","article-title":"Cell cycle regulation by the intrinsically disordered proteins p21 and p27","volume":"40","author":"Yoon","year":"2012","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.canlet.2014.03.012_b0155","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bbrc.2012.09.041","article-title":"Development of mice without Cip\/Kip CDK inhibitors","volume":"427","author":"Tateishi","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.canlet.2014.03.012_b0160","doi-asserted-by":"crossref","first-page":"12030","DOI":"10.1074\/jbc.M010604200","article-title":"The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ","volume":"276","author":"Petronilli","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.canlet.2014.03.012_b0165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.bjp.0706556","article-title":"Mitochondria: a target for cancer therapy","volume":"147","author":"Armstrong","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.canlet.2014.03.012_b0170","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.bbabio.2006.03.014","article-title":"Mitochondrial subpopulations and heterogeneity revealed by confocal imaging: possible physiological role?","volume":"1757","author":"Kuznetsov","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.canlet.2014.03.012_b0175","first-page":"532","article-title":"Bcl-2 proteins and mitochondria\u2013specificity in membrane targeting for death","volume":"2011","author":"Lindsay","year":"1813","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.canlet.2014.03.012_b0180","first-page":"3","article-title":"Apoptosis, oncosis, and necrosis. An overview of cell death","volume":"146","author":"Majno","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.canlet.2014.03.012_b0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/BJ20100814","article-title":"Survivin and IAP proteins in cell-death mechanisms","volume":"430","author":"Altieri","year":"2010","journal-title":"Biochem J"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514001578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514001578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T21:08:21Z","timestamp":1589231301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383514001578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":37,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0304383514001578"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2014.03.012","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HS-438, a new inhibitor of Imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2014.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}